Sotera Health(SHC) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total company revenue increased by 5.7% to $1.164 billion in 2025, or 5.2% growth on a constant currency basis compared to 2024 [4][13] - Adjusted EBITDA rose by 8.2% to $593.8 million, or 7.8% on a constant currency basis, with adjusted EBITDA margins expanding to 51%, an increase of 118 basis points [4][13] - Adjusted EPS for the year was $0.86, an increase of $0.16 versus 2024, driven by operational growth and a lower tax rate [14] Business Line Data and Key Metrics Changes - Sterigenics revenue improved by 10.6% to $198 million, or 8% on a constant currency basis, driven by favorable pricing and volume [11] - Nordion's revenue decreased by 12.3% to $50 million due to unfavorable volume and mix from Cobalt-60 harvest schedules [12] - Nelson Labs revenue increased by 2.3% to $55 million, with segment income rising by 1.9% to $18 million [12][13] Market Data and Key Metrics Changes - Customer satisfaction exceeded 80%, indicating strong service delivery [5] - Revenue from XBU customers expanded by 9% year-over-year, reflecting successful commercial initiatives [5][48] Company Strategy and Development Direction - The company is focused on executing its 2025-2027 long-range plan, emphasizing operational excellence and disciplined capital deployment [7][20] - The construction of a new X-ray facility is planned to open in 2026, aimed at enhancing service offerings across sterilization modalities [5][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive long-term growth and shareholder value, citing a strong balance sheet and cash flow generation [20] - The company expects total revenue for 2026 to increase to a range of $1.233 billion-$1.251 billion, representing 5%-6.5% constant currency growth [8][17] Other Important Information - The company reduced borrowing costs by 75 basis points on its $1.4 billion term loan and paid down $86 million of debt, resulting in annual interest savings of $13 million [6] - Adjusted free cash flow was $210 million in 2025, aligning with the company's goal of achieving $500 million-$600 million in cumulative free cash flow by 2027 [14][15] Q&A Session Summary Question: Guidance and EBITDA margins - The midpoint of the guidance implies about 20 basis points of expansion, driven by normal operating leverage [22][23] Question: Sterigenics client insourcing - There is no significant shift in insourcing; one customer will start bringing volume in late 2025 [24][25] Question: 2026 outlook for Sterigenics - Expecting mid to high single digits constant currency revenue growth for Sterigenics in 2026 [30][31] Question: Nelson Labs margins - Nelson Labs is expected to maintain low to mid 30% margins in 2026, with Q1 being the lightest quarter [32][33] Question: X-ray facility opening - The X-ray facility is expected to open in the second half of 2026, with a ramp-up period for customer qualifications [40][42] Question: Competitive positioning in Sterigenics - Sterigenics is well-positioned despite the NESHAP extension, with strong customer satisfaction and a global service model [66][67] Question: Nordion segment headwinds - The decrease in Nordion's revenue was driven by Cobalt-60 harvest timing, not demand issues [81][83] Question: Onshoring impact - No significant movement towards onshoring has been observed, but the company is well-positioned if it occurs [85][86] Question: Guidance visibility - Volume and mix are the key factors that could drive results towards the higher end of the guidance range [89][90]